PSA Levels Mean More Extensive Prostate Disease In Older Men

May 31, 1998

In a study of prostate cancer at different ages, Johns Hopkins researchers have found that at diagnosis, older men have more extensive disease than younger men even if their prostate specific antigen (PSA) levels are the same. PSA is a protein made by the prostate; rising blood levels suggest that the prostate is enlarged or even cancerous.

"The finding shows that both doctors and older men must be especially vigilant," says H. Ballentine Carter, M.D., associate professor of urology. "The blood test results don't necessarily mean the same level of disease when ages differ," he said. The study, presented May 31 at the annual meeting of the American Urological Association in San Diego, Calif., was done with cancers that could not be detected by digital rectal exams.

The results are a new wrinkle on a long-standing problem over deciding whether to do further testing on men with raised PSA levels, Carter says. "Lowering the PSA threshold means you pick up more small, harmless tumors. Raising the PSA threshold means you're more likely to miss life-threatening tumors. The present study gives us age as an additional guide in deciding when it might be worthwhile to do further testing in men with non-palpable prostate cancer. At any particular PSA level, a key factor in catching cancer when it is still curable is the man's age." The Hopkins team studied 492 men who had undergone surgery to remove their prostates. The men were divided into three age groups (40-50, n=69; 51-60, n=227; 61-73, n=196) and five pre-treatment PSA categories: (2.5-4.0, n=36; 4.1-6.0, n=100; 6.1-8.0, n=122; 8.1-10.0, n=76; >10.0, n=135). Patients were considered curable if the cancer was either confined to the prostate or had not spread outside the gland to lymph nodes and the seminal vesicles.

For a given PSA range, increasing age was associated with lower probability of cure. If a man 40 to 50 years old had a PSA level of 4.0, for example, he had an 89 percent chance of having curable cancer; but a man with the same PSA level who was 61 to 73 years old had only a 78 percent chance of having a curable cancer. For PSA levels of 8.1 to 10, the rates of curable cancer were 73 percent for men ages 40 to 50 and 49 percent for men ages 61 to 73.

Other authors of the study include Jonathan I. Epstein, Patrick C. Walsh and Alan W. Partin.

--JHMI--

Johns Hopkins Medical Institutions' news releases are available on a PRE-EMBARGOED basis on EurekAlert at http://www.eurekalert.org, Newswise at http://www.newswise.com and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to bsimpkin@welchlink.welch.jhu.edu or 76520.560@compuserve.com.

On a POST-EMBARGOED basis find them at http://hopkins.med.jhu.edu, Quadnet at http://www.quad-net.com, ScienceDaily at http://www.sciencedaily.com or on CompuServe in the SciNews-MedNews library of the Journalism Forum under file extension ".jhm".

Media contact: Marc Kusinitz (410)955-8665
E-mail: mkusinit@welchlink.welch.jhu.edu
-end-


Johns Hopkins Medicine

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.